Unknown

Dataset Information

0

Adapting clinical trial design to maintain meaningful outcomes during a multicenter asthma trial in the precision medicine era.


ABSTRACT: Precision medicine is expected to impact the care of people with asthma, given its high disease prevalence, heterogeneity of pathophysiologic mechanisms, and consequent clinical phenotypes. A novel phenotype-stratified clinical trial conducted by the NHLBI AsthmaNet Consortium, titled Steroids in Eosinophil Negative Asthma (SIENA), was a randomized, multicenter, clinical trial that prospectively stratified individuals according to their baseline level of sputum inflammation during a screening period. Two phenotypic strata were assigned based on an a priori defined extent of sputum eosinophilia (Eos Low versus Eos High). This article describes: the scientific premise for the trial design, including assumptions used for power calculations; modifications to the analysis plan implemented after the trial started due to a higher than expected prevalence of one phenotypic stratum which impacted the ability to accrue sufficient subjects within the planned budget and study period; investigator alternatives to address the strata imbalance weighing scientific impact and study feasibility; and the final modified SIENA study design and analysis plan. SIENA was successfully completed in a manner that maintained meaningful outcomes. We conclude with recommendations for incorporation of pre-specified contingency plans into phenotype-directed protocols, to address the potential for differences in observed compared to estimated prevalence of different phenotypes in a study population. These approaches can be applied to precision medicine trials for the future.

SUBMITTER: Sorkness CA 

PROVIDER: S-EPMC6425934 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications


Precision medicine is expected to impact the care of people with asthma, given its high disease prevalence, heterogeneity of pathophysiologic mechanisms, and consequent clinical phenotypes. A novel phenotype-stratified clinical trial conducted by the NHLBI AsthmaNet Consortium, titled Steroids in Eosinophil Negative Asthma (SIENA), was a randomized, multicenter, clinical trial that prospectively stratified individuals according to their baseline level of sputum inflammation during a screening pe  ...[more]

Similar Datasets

| S-EPMC5543186 | biostudies-other
| S-EPMC8123613 | biostudies-literature
| S-EPMC6396357 | biostudies-literature
| S-EPMC4828749 | biostudies-literature
| S-EPMC6901987 | biostudies-literature
| S-EPMC6287751 | biostudies-literature
| S-EPMC4505624 | biostudies-literature
| S-EPMC5404028 | biostudies-literature
| S-EPMC4613446 | biostudies-literature
| S-EPMC8113113 | biostudies-literature